Can Trazodone Be Bad for Your Liver?

Trazodone can harm the liver, but the risk is low for most people taking it at standard doses. At normal doses, the drug sometimes causes modest rises in liver enzyme levels that typically don’t require any change in treatment. Severe liver injury, including acute liver failure and even death, has been documented but remains rare. The full picture involves your genetics, other medications you take, and how quickly the problem gets caught.

How Common Is Liver Damage From Trazodone

Trazodone has been prescribed in North America since the early 1980s, and over those decades the number of reported serious liver injury cases remains small relative to how widely the drug is used.¹ The pattern that emerges from published case reports and reviews is consistent: mild enzyme elevations are not uncommon, but they tend to stay modest and resolve on their own. Full-blown hepatotoxicity, the kind that lands someone in the hospital, is the exception rather than the rule.²

That said, “rare” is not the same as “impossible.” Reviews of antidepressant-related liver injury have linked trazodone to cases of death among users, placing it alongside drugs like nefazodone, duloxetine, bupropion, and sertraline in that regard.³ So while the overwhelming majority of people taking trazodone will never experience meaningful liver problems, the consequences when things do go wrong can be serious. The challenge is knowing when to worry and when to relax.

What Trazodone Does Inside Liver Cells

Your liver is the main organ responsible for breaking down trazodone, and that breakdown process is where the trouble starts. The liver’s enzymes, particularly one called CYP3A4, metabolize trazodone into several byproducts. Some of these intermediate compounds are chemically reactive and can damage liver cells before they’re fully neutralized.⁴ One metabolite in particular, called m-CPP, has been singled out as a potential culprit.

In laboratory studies on rat liver cells, trazodone triggered a cascade of damage: a surge in harmful oxygen-containing molecules, a buildup of byproducts from damaged cell membranes, depletion of glutathione (a key protective molecule the liver relies on to mop up toxic compounds), and a collapse of the energy-producing structures inside cells.⁵ When researchers blocked the CYP3A4 enzyme before exposing liver cells to trazodone, the toxicity dropped, which strongly suggests the damage is caused by the breakdown products rather than by trazodone itself.⁶

Studies in human liver cells have confirmed part of this picture. After a day of exposure, trazodone collapsed the energy-producing potential of liver cells and depleted their glutathione stores, leading to cell death.⁷ The key takeaway is that the liver is not just passively filtering out trazodone; the act of breaking it down generates compounds that can, in the right circumstances, harm the organ doing the work.

When Liver Injury Shows Up and What It Looks Like

One of the tricky aspects of trazodone-related liver injury is the timeline. It doesn’t always appear in the first week or even the first month. A broad review of antidepressant liver injury found that the window between starting treatment and the onset of liver damage generally falls somewhere between a few days and six months.⁸ In one published case, a patient developed damage after just four days of use at a moderate dose.⁹ In another, it took 18 months.¹ Liver toxicity has even appeared after the drug was already stopped.²

The type of liver injury varies, too. The most common pattern is hepatocellular, meaning the liver cells themselves are damaged and leak enzymes into the bloodstream. But mixed patterns and cholestatic injury, where the flow of bile is blocked, have also been documented.² Trazodone has been formally associated with both hepatocellular injury and cholestasis, with the mechanisms still not entirely understood.¹⁰

From a symptom standpoint, you should be alert to jaundice (yellowing of the skin or eyes), dark urine, unusually pale stools, persistent nausea, abdominal pain concentrated under the right ribs, and unusual fatigue. These symptoms can be subtle at first, and the wide time window for onset means it’s easy to miss the connection to a medication started weeks or months earlier.

Your Genes Might Be Part of the Problem

Not everyone metabolizes trazodone the same way, and genetic variation in liver enzymes is emerging as a significant piece of the puzzle. A second enzyme called CYP2D6, besides the primary CYP3A4, also plays a role in trazodone metabolism. Some people carry gene variants that make their version of CYP2D6 sluggish or nonfunctional. When CYP2D6 isn’t working well, the potentially toxic metabolite m-CPP can accumulate instead of being cleared efficiently.

A pharmacogenomic study found that people whose CYP2D6 activity was predicted to be poor were about nine times more likely to develop adverse drug reactions when taking trazodone, compared to those with normal enzyme function.¹¹ That’s a striking difference for a drug typically thought of as well tolerated.

There’s also the issue of drug interactions mimicking genetic slowness. In one case, a patient taking trazodone alongside escitalopram (a common SSRI antidepressant) developed liver injury. Pharmacogenomic testing revealed the patient already had a CYP2D6 gene variant, and escitalopram, which itself inhibits CYP2D6, essentially doubled down on the problem. The result was a drug-drug-gene interaction: the combination of inherent genetic vulnerability and an interacting medication pushed m-CPP levels high enough to damage the liver.¹² This kind of interaction is worth knowing about because trazodone and SSRIs are often prescribed together, particularly when trazodone is being used for insomnia on top of another antidepressant.

How Trazodone Compares to Its Close Relative Nefazodone

If you’ve heard alarm bells about liver damage and antidepressants, you might be thinking of nefazodone. Trazodone and nefazodone are chemically related, but their liver safety profiles are not in the same league. Nefazodone earned a black-box warning from the FDA for hepatotoxicity and was eventually pulled from the U.S. market by its original manufacturer because of the risk. Trazodone has never received a similar warning.

Lab comparisons back this up. In head-to-head testing of the two drugs alongside buspirone (another anxiolytic), nefazodone was by far the most toxic compound to liver cells. Trazodone had relatively modest effects, and buspirone showed the least toxicity.¹³ One specific mechanism illustrates the difference well: nefazodone strongly inhibited the bile salt export pump, a transporter that liver cells depend on to clear bile acids. Trazodone had no effect on this transport system at all.¹⁴ Bile acid buildup is one of the ways drugs poison liver cells, so the absence of this effect with trazodone is a meaningful safety advantage.

Both drugs can generate oxidative stress in liver cells at high enough concentrations, but the dose at which trazodone starts causing problems in the lab is significantly higher than for nefazodone. The clinical track record reflects this: nefazodone caused liver failure frequently enough to be removed from the market, while trazodone’s cases remain scattered. If you’ve been told to avoid nefazodone and are wondering whether trazodone is similarly dangerous, the short answer is no, though “safer” isn’t the same as “risk-free.”

What Happens When the Drug Is Stopped

The encouraging news from published case reports is that trazodone-related liver injury is often reversible once the drug is discontinued. In one well-documented case, a patient who developed acute hepatitis after just four days on trazodone saw liver function tests improve dramatically within ten days of stopping the medication.⁹ Another case report explicitly describes “acute reversible liver injury” following protracted trazodone use.¹

But not every case resolves that cleanly. At the severe end, a 57-year-old man with no prior medical history developed acute liver failure three months after starting trazodone (alongside diazepam). His liver enzymes were extraordinarily elevated, with ALT reaching over 4,600 U/L and AST over 2,700 U/L, both far above normal upper limits of roughly 40-50 U/L.² In another severe case, a 48-year-old woman with no history of liver disease developed fulminant liver failure after four months on a combination of venlafaxine and trazodone, ultimately requiring a liver transplant to survive.¹⁵

These extremes underscore why early detection matters. The difference between “stop the drug and recover fully in a couple weeks” and “need a new liver” often comes down to how quickly the injury is recognized. That wide timeline mentioned earlier, days to months, makes this harder than it sounds in practice. A minor elevation caught on routine blood work is manageable. By the time deep jaundice sets in, the damage may be far more advanced.

Practical Monitoring If You Take Trazodone

No formal guideline mandates routine liver testing for everyone on trazodone, which reflects the drug’s overall safety profile. But a few situations warrant extra attention:

Starting a new prescription: If your doctor orders baseline blood work before or shortly after starting trazodone, that gives a reference point for comparison. An initial liver panel makes later changes easier to interpret.
Taking other drugs that affect CYP2D6 or CYP3A4: Common medications in these categories include certain SSRIs (like paroxetine and fluoxetine), some antifungal drugs, and certain antibiotics. If you’re combining trazodone with any of these, the interplay could slow trazodone metabolism and increase the buildup of harmful byproducts.⁴
Known CYP2D6 poor metabolizer status: If you’ve had pharmacogenomic testing and know your CYP2D6 function is reduced, this is worth discussing with your prescriber. The roughly ninefold increase in adverse reaction risk among poor metabolizers is a meaningful finding.¹¹
Pre-existing liver disease: A liver that’s already compromised has less reserve capacity to handle toxic metabolites. Extra caution and more frequent monitoring make sense in this scenario.

If you notice any of the warning signs mentioned earlier, particularly jaundice, dark urine, or new right-upper-quadrant abdominal pain, contact your doctor promptly rather than waiting for your next scheduled visit. The pattern of a rapid rise and then fall in liver enzymes after drug discontinuation is one of the hallmarks of drug-induced liver injury, and catching it during the “rise” phase gives the best chance of a straightforward recovery.⁹

Why This Side Effect Stays Under the Radar

Drug-induced liver injury, across all medications, is an underappreciated problem. It’s the leading cause of acute liver failure in many Western countries, yet for any individual drug, the incidence tends to be low enough that it doesn’t show up reliably in clinical trials, which typically enroll hundreds to a few thousand participants. Trazodone’s rarity of serious hepatotoxicity means most prescribers have never personally encountered a case. That’s actually a good sign for patients, but it also means awareness can be low.

The idiosyncratic nature of the reaction compounds the problem. “Idiosyncratic” in this context means the injury isn’t dose-dependent in a straightforward way: it’s not that higher doses always cause more damage. Instead, it strikes certain individuals for reasons that probably involve their unique combination of genetics, other medications, and possibly underlying liver health. Both the four-day case and the 18-month case occurred at standard therapeutic doses. The 48-year-old woman who needed a transplant was also on normal doses.¹⁵ This unpredictability is exactly why blanket reassurance (“the dose is low, so don’t worry”) is incomplete.

Alcohol, Supplements, and Other Liver Stressors

Anything that adds strain to the liver’s detoxification workload is worth thinking about when you’re on a medication that occasionally causes liver injury. Alcohol is the obvious one. Regular heavy drinking depletes glutathione, the same protective molecule that trazodone’s metabolism consumes. Drinking while taking trazodone doesn’t guarantee liver damage, but it removes one of the liver’s built-in safety nets.

Herbal supplements are a less obvious concern. Products containing green tea extract, kava, comfrey, or high-dose vitamin A have their own track records of liver injury. Combining them with a prescription drug that has even a small hepatotoxic potential is an unnecessary gamble. Many people don’t mention supplements to their prescribers, and many prescribers don’t ask. If you’re taking trazodone, it’s worth volunteering that information.

Acetaminophen (Tylenol) is another medication processed partly through CYP3A4, the same enzyme pathway that activates trazodone. At recommended doses acetaminophen is safe for most people, but chronic use or doses above the recommended ceiling while also taking trazodone could theoretically push the shared enzymatic pathway harder. This isn’t a well-studied interaction specifically, but the biochemistry suggests caution with regular high-dose acetaminophen use.

The Role of Pharmacogenomic Testing

Pharmacogenomic testing, which analyzes your DNA to predict how you metabolize certain drugs, is becoming more accessible and less expensive. For trazodone specifically, knowing your CYP2D6 status could meaningfully change your risk picture. About 5-10% of people of European descent are poor CYP2D6 metabolizers, meaning the enzyme works slowly or not at all. In other populations the rates vary.

The case report describing a drug-drug-gene interaction between trazodone and escitalopram concluded that targeted pharmacogenomic testing could help minimize the risk of drug-induced liver injury in situations where multiple CYP-interacting drugs are being used.¹² This isn’t yet standard practice before prescribing trazodone, and given the overall rarity of severe liver injury it’s hard to justify testing everyone. But if you’re already on multiple medications that interact with these enzyme pathways, or if you’ve had unexplained liver enzyme elevations on previous drugs, bringing up testing with your doctor is reasonable. Some insurers now cover it, and direct-to-consumer tests can identify your CYP2D6 status, though the clinical-grade tests ordered through a healthcare provider tend to be more comprehensive and actionable.

1
PubMed. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity
2
PubMed Central. Acute Liver Failure due to Trazodone and Diazepam
3
PubMed. Liver injury associated with antidepressants
4
PubMed Central. Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease
5
PubMed. Mechanisms of trazodone-induced cytotoxicity and the protective effects of melatonin and/or taurine toward freshly isolated rat hepatocytes
6
PubMed. Evaluating the Role of Drug Metabolism and Reactive Intermediates in Trazodone-Induced Cytotoxicity toward Freshly-Isolated Rat Hepatocytes
7
PubMed. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone
8
PubMed. Antidepressant-induced liver injury: a review for clinicians
9
PubMed. Hepatotoxicity after short-term trazodone therapy
10
Gastroenterology Clinics of North America. Hepatotoxicity of Anesthetics and Other Central Nervous System Drugs
11
PubMed Central. CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone An Explorative Pharmacogenetic Study
12
PubMed. CYP2D6 polymorphism may contribute to Trazodone-induced hepatotoxicity: a rare case of drug-drug-gene induced liver injury
13
Toxicological Sciences. In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone
14
Toxicological Sciences. Inhibition of Hepatobiliary Transport as a Predictive Method for Clinical Hepatotoxicity of Nefazodone
15
PubMed. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report